Nearly four years after its start, a phase III trial of Gamida Cell Ltd.'s ex vivo expanded cord blood candidate, omidubicel, for hematologic malignancies is fully enrolled, the company said. Read More
The natural immune system has two lines of defense that complement each other. In response to an infection, a rapid but fairly unspecific and short-lived response by the innate immune system is followed by the precisely targeted attack of the B and T cells of the adaptive immune system, followed by immune memory that can last a lifetime Read More
With many on Wall Street transfixed by the three injectable calcitonin gene-related peptide (CGRP) therapies cleared in the prophylactic migraine market, Satsuma Pharmaceuticals Inc.’s prospects with STS-101 may have gone overlooked, at least until lately. Read More
Making the obvious nonobvious isn’t as simple as observing something others have missed, the U.S. Court of Appeals for the Federal Circuit reiterated in a precedential opinion last week. Read More
Drug diversion in hospitals is a serious concern, facilitated in part by inadequate security controls that allow unauthorized staff to access the pharmacy stock. To help thwart this problem and improve medication management, Taipei, Taiwan-based Cyberlink Corp. and Imedtac Co. Ltd. are teaming up to bring facial recognition technology to the hospital medicine cabinet. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations. Read More
